Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | PROMISE-1: eptinezumab in episodic migraine

Messoud Ashina • 29 May 2020
EAN 2020
Headache Antibodies Eptinezumab
PROMISE-1

Messoud Ashina, MD, PhD, DMSc, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, discusses the PROMISE-1 study (NCT02559895), which evaluated the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Messoud Ashina

The PEARL study: real-world effectiveness of fremanezumab for the preventive treatment of migraine
3:47
The PEARL study: real-world effectiveness of fremanezumab for the preventive treatment of migraine
Messoud Ashina • 30 Jun 2025
Post-hoc analysis of PEARL: early initiation of fremanezumab for the prevention of migraine
3:10
Post-hoc analysis of PEARL: early initiation of fremanezumab for the prevention of migraine
Messoud Ashina • 30 Jun 2025
Reflecting on EAN 2025: advancing migraine treatment
1:39
Reflecting on EAN 2025: advancing migraine treatment
Messoud Ashina • 30 Jun 2025
The burden of migraine: from individuals to society
2:43
The burden of migraine: from individuals to society
Messoud Ashina • 23 Jun 2022

Related Videos

PACAP-38 is increased in the tear fluid of patients with migraine
1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
TRIPLE study: triple combination therapy for chronic migraine
2:41
TRIPLE study: triple combination therapy for chronic migraine
Marina Romozzi • 27 Jun 2026
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
8:49
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
Richard Lipton • 1 Jul 2026
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
5:05
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
Richard Lipton • 1 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals